- Home
- BDTX vs MIN Comparison
BDTX vs MIN Comparison
Compare BDTX & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | MIN |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 278.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDTX | MIN |
|---|---|---|
| Price | $2.35 | $2.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 224.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.31% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $2.41 |
| 52 Week High | $4.94 | $2.72 |
Technical Indicators
Market Signals| Indicator | BDTX | MIN |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 45.09 |
| Support Level | $2.28 | $2.41 |
| Resistance Level | $2.47 | $2.52 |
| Average True Range (ATR) | 0.36 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 5.52 | 36.25 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.